Driving relevance means driving growth. Join global brands and industry thought leaders at Brandweek, Sept. 11–14 in Miami, for actionable takeaways to better your marketing. 50% off passes ends April 10.
Johnson & Johnson’s worldwide year-over-year sales declined 10.8% in the second quarter of 2020, as fewer consumers had elective surgery or opted to buy beauty products during the pandemic.
The company’s medical device segment dropped 33.9% to $4.3 billion, while its consumer health division, which includes skin care brands Neutrogena and Aveeno, fell 7% to $3.3 billion. The New Jersey-based healthcare products manufacturer noted, however, that sales of Tylenol and Listerine mouthwash were strong, helping to mitigate the overall loss.
J&J’s
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in